Choose Retatrutide If: Maximum weight loss is the primary goal Previous GLP-1 agonists produced significant nausea (GIP component may help) No specific liver health concerns requiring treatment Tolerance for slightly higher GI side effects during titration Response to dual agonists (like tirzepatide) has been positive Choose Survodutide If: Liver health concerns exist (fatty liver, MASH, elevated liver enzymes) Moderate weight loss goals rather than maximum efficacy priority Interest in potential cardiovascular outcome benefits (CVOT data pending) Preference for a compound with FDA Breakthrough Therapy designation Plans to potentially transition to approved medication once available For most people focused primarily on weight loss, Retatrutide presents the stronger option based on available data
Many GPs are not proactive about raising weight management medications
FAQs About GLP-1 and GIP/GLP-1s for Obesity 9 Cost is one of the biggest barriers to taking GLP-1s or dual GIP/GLP-1 agonists
In China, global wellness trends are increasingly influencing consumer choices, and yerba mate is gaining traction as a natural substitute for tea and coffee, supported by beverage companies launching yerba mateinfused teas and energy drinks
These large reductions in weight by current incretin therapeutics have translated into improvements in cardiovascular health
(PubMed) Carr AC, Rosengrave PC, Bayer S, Chambers S, Mehrtens J, Shaw GM
